A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (117 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-05-05. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 11.5% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: patientplacebo controlledare excludedascendingprimary
  Phrases that lowered it: healthyadultsingleand safetypharmacokinetics
• Phase: 1 (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Sponsor's past trials: 1010 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 70 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Design: sequential (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: double (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 45 (lowers risk) · Who can join
• Number of arms: 7 (lowers risk) · Design
• Disease area, psychiatry: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects NCT05845996 · started 2018 · scored riskier than 10% of active trials completed
• A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects NCT05846009 · started 2020 · scored riskier than 6% of active trials completed
• First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects NCT04521738 · started 2019 · scored riskier than 10% of active trials completed
• Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants NCT05795907 · started 2020 · scored riskier than 7% of active trials completed
• Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects NCT01537640 · started 2012 · scored riskier than 2% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.